When I gave my target price of $18 (now $180) years ago, it was iPlex I was waiting for. I'm among the group of people who think iPlex is still a valuable part of Insmed (admittedly with it being backburnered for now). Arikace is the primary function right now.....for whatever the potential is. But, to me, iPlex is still the king. Shoot, I still believe that INSM-18 and igfbp3 will make news for cancer....although I realize (as it has been so often been commented here) it will take deep pockets of money for that. And, to show you how looney I may be, I still hold out hopes for the resurrection of the phoenix, so to speak, of INS-1
Ahhhh......18 tomorrow. Well, if it happens and I get my act together I just might sell a few shares in honor of my original number. Of course, my new number is now 180..... I hope everyone will forgive me.
Wasn't it Dr. Joshua Schimmer who made the Piper Jaffray target? I believe he used to be with Lazard and was probably with them when they made their call at $28 If this is the same person, he has become more optimistic with regards to Insmed's short term potential. Can anyone confirm?
Piper Jaffray Expands Biotechnology Research Platform with Addition of Josh Schimmer, MD
11/7/2013 9:53:35 AM
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 7, 2013-- Piper Jaffray (NYSE: PJC) is pleased to announce the hiring of Josh Schimmer, MD as a managing director and senior research analyst based in the firm’s New York office. Schimmer will be focused on small- and mid-cap biotechnology companies with specific emphasis in core therapeutic areas, commercialization and strategic partnerships.
Schimmer brings more than 10 years of experience to Piper Jaffray. He joined the firm from Lazard Capital Markets, and was previously at Cowen & Co., Leerink Swann, Deutsche Banc and Davidson Kempner. Schimmer holds a doctorate of medicine from the University of Toronto and a Master of Business Administration degree from Harvard Business School.
"Piper Jaffray has a strong team of healthcare professionals and we are excited to be adding another research specialist in biotechnology with Josh's hire," commented Steph Wissink, co-director of equity research for Piper Jaffray. "With increased emphasis on core growth areas of biotech, we see opportunities to serve the needs of our clients and build upon our market-leading healthcare platform."
Good to see you still around, sartorial. I think you have even been here longer than me. I got in late 2001.....for completely different reasons, obviously, than Arikace. I hope to see, as Paul Harvey would have said, the "rest of the story" for iPlex.
.....but did you all realize the MUSICAL EVENT OF THE YEAR will be happening this coming Thursday evening?? That's right.....Carrie Underwood will be performing the stage version of The Sound of Music and it will be televised LIVE on NBC. Enjoy
LOL....yeah, sometimes that happens to me, too. Happy Thanksgiving to you and your family, as well, Levonchiko. I concur with your thoughts of looking for a nice Christmas present. That would be sweet!!
1) I think so.....it was borderline.....can anyone verify?
OK, good enough. I'm going to celebrate at Harrah's tomorrow. BO, will you be there tomorrow?
HAPPY THANKSGIVING ALL!!!
Did I miss the headline of that? I know about it from last night but haven't seen it today. Where did you see the above?
OK, I see I am certainly out of my league with you, Cindy. I assume you covered your $15.02 short? Cindy, I see you haven't gotten into the spirit of the Thanksgiving/Christmas season yet. Usually people tend to curb in their pomposity at this time of year.
Since I don't know what you mean by the first sentence, I don't know if I agree with the second sentence (but you well may be right). Could you please expound more, Cindy?